Pfizer and BioNTech report positive data for mRNA combination vaccine targeting influenza and COVID-19.

Global Banking News-October 26, 2023-Pfizer and BioNTech report positive data for mRNA combination vaccine targeting influenza and COVID-19

(C)2023 ENPublishing - http://www.enpublishing.co.uk

US biopharmaceutical company Pfizer Inc (NYSE:PFE) and its partner, German biotechnology company BioNTech SE (Nasdaq:BNTX), announced on Thursday promising topline results from a Phase 1/2 study assessing mRNA-based combination vaccine candidates for influenza and COVID-19.

In the trial, these vaccines generated robust immune responses to influenza A, influenza B and SARS-CoV-2 strains in healthy adults aged 18 to 64. The safety profile resembled that of the companies' COVID-19 vaccine.

A pivotal Phase 3 trial for the lead formulations is expected to commence in the coming months.

Annaliesa Anderson, Pfizer's senior vice president and head of Vaccine Research and Development, expressed optimism about the...

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT